nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadopentetate dimeglumine—PGD—Methotrexate—systemic scleroderma	0.696	1	CbGbCtD
Gadopentetate dimeglumine—Rash—Mometasone—systemic scleroderma	0.000292	0.000962	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Captopril—systemic scleroderma	0.000292	0.000961	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Mometasone—systemic scleroderma	0.000292	0.000961	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Leflunomide—systemic scleroderma	0.000292	0.00096	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000292	0.00096	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Lisinopril—systemic scleroderma	0.000291	0.000957	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000291	0.000956	CcSEcCtD
Gadopentetate dimeglumine—Headache—Mometasone—systemic scleroderma	0.00029	0.000956	CcSEcCtD
Gadopentetate dimeglumine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000955	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00029	0.000953	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Leflunomide—systemic scleroderma	0.000289	0.000952	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000288	0.000949	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Captopril—systemic scleroderma	0.000288	0.000948	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000287	0.000946	CcSEcCtD
Gadopentetate dimeglumine—Pain—Leflunomide—systemic scleroderma	0.000287	0.000944	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Leflunomide—systemic scleroderma	0.000287	0.000944	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000285	0.000939	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000285	0.000937	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000284	0.000936	CcSEcCtD
Gadopentetate dimeglumine—Shock—Lisinopril—systemic scleroderma	0.000284	0.000934	CcSEcCtD
Gadopentetate dimeglumine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000283	0.000931	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Lisinopril—systemic scleroderma	0.000281	0.000926	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Azathioprine—systemic scleroderma	0.000281	0.000924	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Azathioprine—systemic scleroderma	0.000281	0.000924	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Lisinopril—systemic scleroderma	0.00028	0.000922	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000919	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000279	0.000917	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Captopril—systemic scleroderma	0.000279	0.000917	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000278	0.000916	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000914	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000276	0.00091	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000276	0.00091	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000276	0.000908	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Mometasone—systemic scleroderma	0.000275	0.000906	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Lisinopril—systemic scleroderma	0.000275	0.000905	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000274	0.000903	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Mycophenolic acid—systemic scleroderma	0.000274	0.000901	CcSEcCtD
Gadopentetate dimeglumine—Pain—Mycophenolic acid—systemic scleroderma	0.000274	0.000901	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000272	0.000895	CcSEcCtD
Gadopentetate dimeglumine—Cough—Mycophenolate mofetil—systemic scleroderma	0.00027	0.000889	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Lisinopril—systemic scleroderma	0.000269	0.000887	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Captopril—systemic scleroderma	0.000269	0.000886	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000268	0.000883	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000267	0.00088	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Leflunomide—systemic scleroderma	0.000267	0.000877	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Leflunomide—systemic scleroderma	0.000265	0.000873	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Leflunomide—systemic scleroderma	0.000265	0.000873	CcSEcCtD
Gadopentetate dimeglumine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000265	0.000871	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000264	0.000868	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000867	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000867	CcSEcCtD
Gadopentetate dimeglumine—Myocardial infarction—Prednisone—systemic scleroderma	0.000263	0.000866	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000263	0.000865	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000864	CcSEcCtD
Gadopentetate dimeglumine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000262	0.000863	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000262	0.000862	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000262	0.000862	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000861	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Lisinopril—systemic scleroderma	0.000259	0.000852	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Captopril—systemic scleroderma	0.000259	0.000852	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000258	0.000848	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Lisinopril—systemic scleroderma	0.000257	0.000846	CcSEcCtD
Gadopentetate dimeglumine—Rash—Captopril—systemic scleroderma	0.000257	0.000845	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Captopril—systemic scleroderma	0.000256	0.000844	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Lisinopril—systemic scleroderma	0.000256	0.000844	CcSEcCtD
Gadopentetate dimeglumine—Headache—Captopril—systemic scleroderma	0.000255	0.000839	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000838	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000253	0.000833	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000253	0.000833	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000253	0.000831	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Lisinopril—systemic scleroderma	0.000251	0.000825	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000249	0.000819	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Lisinopril—systemic scleroderma	0.000249	0.000818	CcSEcCtD
Gadopentetate dimeglumine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000818	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000815	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000247	0.000814	CcSEcCtD
Gadopentetate dimeglumine—Pain—Lisinopril—systemic scleroderma	0.000247	0.000812	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Lisinopril—systemic scleroderma	0.000247	0.000812	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000247	0.000812	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000245	0.000808	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Prednisone—systemic scleroderma	0.000245	0.000808	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000804	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Azathioprine—systemic scleroderma	0.000243	0.0008	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Captopril—systemic scleroderma	0.000242	0.000796	CcSEcCtD
Gadopentetate dimeglumine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000241	0.000794	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000793	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Leflunomide—systemic scleroderma	0.000241	0.000792	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000238	0.000782	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Leflunomide—systemic scleroderma	0.000237	0.000781	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000237	0.00078	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000236	0.000777	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000236	0.000776	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Azathioprine—systemic scleroderma	0.000235	0.000773	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000758	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00023	0.000756	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Leflunomide—systemic scleroderma	0.00023	0.000756	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Lisinopril—systemic scleroderma	0.000229	0.000754	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Lisinopril—systemic scleroderma	0.000228	0.00075	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Lisinopril—systemic scleroderma	0.000228	0.00075	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000747	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000226	0.000745	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Azathioprine—systemic scleroderma	0.000226	0.000744	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Prednisone—systemic scleroderma	0.000225	0.000741	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000225	0.000741	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000225	0.000739	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Methotrexate—systemic scleroderma	0.000224	0.000739	CcSEcCtD
Gadopentetate dimeglumine—Rash—Azathioprine—systemic scleroderma	0.000224	0.000737	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Azathioprine—systemic scleroderma	0.000224	0.000737	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Prednisone—systemic scleroderma	0.000224	0.000736	CcSEcCtD
Gadopentetate dimeglumine—Headache—Azathioprine—systemic scleroderma	0.000223	0.000733	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Leflunomide—systemic scleroderma	0.000222	0.00073	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Methotrexate—systemic scleroderma	0.000221	0.000726	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00022	0.000723	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000219	0.000721	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Prednisone—systemic scleroderma	0.000219	0.00072	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000218	0.000718	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000718	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Prednisone—systemic scleroderma	0.000218	0.000717	CcSEcCtD
Gadopentetate dimeglumine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000711	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000711	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Prednisone—systemic scleroderma	0.000215	0.000709	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Methotrexate—systemic scleroderma	0.000215	0.000708	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Leflunomide—systemic scleroderma	0.000213	0.000702	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000212	0.000699	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000212	0.000698	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000212	0.000697	CcSEcCtD
Gadopentetate dimeglumine—Rash—Leflunomide—systemic scleroderma	0.000212	0.000696	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Leflunomide—systemic scleroderma	0.000211	0.000696	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Prednisone—systemic scleroderma	0.000211	0.000695	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Azathioprine—systemic scleroderma	0.000211	0.000695	CcSEcCtD
Gadopentetate dimeglumine—Headache—Leflunomide—systemic scleroderma	0.00021	0.000692	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Prednisone—systemic scleroderma	0.00021	0.000691	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000208	0.000685	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Lisinopril—systemic scleroderma	0.000207	0.000681	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00068	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Lisinopril—systemic scleroderma	0.000204	0.000671	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000204	0.00067	CcSEcCtD
Gadopentetate dimeglumine—Rash—Mycophenolic acid—systemic scleroderma	0.000202	0.000664	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000202	0.000664	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000661	CcSEcCtD
Gadopentetate dimeglumine—Headache—Mycophenolic acid—systemic scleroderma	0.000201	0.00066	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Leflunomide—systemic scleroderma	0.000199	0.000656	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000199	0.000655	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Methotrexate—systemic scleroderma	0.000197	0.00065	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Lisinopril—systemic scleroderma	0.000197	0.000649	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Methotrexate—systemic scleroderma	0.000194	0.000639	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Prednisone—systemic scleroderma	0.000193	0.000635	CcSEcCtD
Gadopentetate dimeglumine—Angioedema—Prednisone—systemic scleroderma	0.000192	0.000631	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Lisinopril—systemic scleroderma	0.000191	0.000628	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Methotrexate—systemic scleroderma	0.00019	0.000627	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Mycophenolic acid—systemic scleroderma	0.00019	0.000626	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Prednisone—systemic scleroderma	0.000189	0.000623	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Methotrexate—systemic scleroderma	0.000188	0.00062	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Prednisone—systemic scleroderma	0.000188	0.000619	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Methotrexate—systemic scleroderma	0.000188	0.000618	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000187	0.000615	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000613	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Prednisone—systemic scleroderma	0.000184	0.000607	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Lisinopril—systemic scleroderma	0.000183	0.000603	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Methotrexate—systemic scleroderma	0.000183	0.000602	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Methotrexate—systemic scleroderma	0.000182	0.000599	CcSEcCtD
Gadopentetate dimeglumine—Rash—Lisinopril—systemic scleroderma	0.000182	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Prednisone—systemic scleroderma	0.000182	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Lisinopril—systemic scleroderma	0.000182	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000182	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000597	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Prednisone—systemic scleroderma	0.000181	0.000596	CcSEcCtD
Gadopentetate dimeglumine—Chills—Methotrexate—systemic scleroderma	0.000181	0.000595	CcSEcCtD
Gadopentetate dimeglumine—Headache—Lisinopril—systemic scleroderma	0.000181	0.000595	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000588	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Prednisone—systemic scleroderma	0.000179	0.000588	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Prednisone—systemic scleroderma	0.000178	0.000586	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000177	0.000584	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Methotrexate—systemic scleroderma	0.000176	0.000581	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Methotrexate—systemic scleroderma	0.000175	0.000577	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000569	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Methotrexate—systemic scleroderma	0.000172	0.000565	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Lisinopril—systemic scleroderma	0.000171	0.000564	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000171	0.000564	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Methotrexate—systemic scleroderma	0.00017	0.000558	CcSEcCtD
Gadopentetate dimeglumine—Shock—Prednisone—systemic scleroderma	0.000168	0.000555	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Prednisone—systemic scleroderma	0.000168	0.000553	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Prednisone—systemic scleroderma	0.000167	0.00055	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000167	0.00055	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Prednisone—systemic scleroderma	0.000166	0.000547	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000166	0.000545	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Prednisone—systemic scleroderma	0.000163	0.000537	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000161	0.000529	CcSEcCtD
Gadopentetate dimeglumine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000524	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000524	CcSEcCtD
Gadopentetate dimeglumine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000521	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Methotrexate—systemic scleroderma	0.000158	0.00052	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000156	0.000513	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Prednisone—systemic scleroderma	0.000154	0.000506	CcSEcCtD
Gadopentetate dimeglumine—Cough—Methotrexate—systemic scleroderma	0.000153	0.000504	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Methotrexate—systemic scleroderma	0.000152	0.0005	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000494	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Methotrexate—systemic scleroderma	0.000149	0.000491	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Methotrexate—systemic scleroderma	0.000149	0.000491	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Prednisone—systemic scleroderma	0.000149	0.00049	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000148	0.000488	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Prednisone—systemic scleroderma	0.000148	0.000486	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Prednisone—systemic scleroderma	0.000146	0.000482	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Methotrexate—systemic scleroderma	0.000144	0.000475	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000143	0.000471	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Prednisone—systemic scleroderma	0.000141	0.000464	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Methotrexate—systemic scleroderma	0.00014	0.000462	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00014	0.000461	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Methotrexate—systemic scleroderma	0.000139	0.000458	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000138	0.000455	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Methotrexate—systemic scleroderma	0.000136	0.000449	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Prednisone—systemic scleroderma	0.000136	0.000448	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Prednisone—systemic scleroderma	0.000135	0.000446	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Prednisone—systemic scleroderma	0.000135	0.000446	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Methotrexate—systemic scleroderma	0.000134	0.00044	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00013	0.000429	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Methotrexate—systemic scleroderma	0.000128	0.000423	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Methotrexate—systemic scleroderma	0.000128	0.00042	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Methotrexate—systemic scleroderma	0.000127	0.000419	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Prednisone—systemic scleroderma	0.000126	0.000415	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Methotrexate—systemic scleroderma	0.000124	0.000409	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000124	0.000407	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Methotrexate—systemic scleroderma	0.000123	0.000406	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Prednisone—systemic scleroderma	0.000123	0.000404	CcSEcCtD
Gadopentetate dimeglumine—Pain—Methotrexate—systemic scleroderma	0.000122	0.000403	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Prednisone—systemic scleroderma	0.000121	0.000399	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000118	0.000388	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Prednisone—systemic scleroderma	0.000117	0.000386	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000117	0.000385	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Methotrexate—systemic scleroderma	0.000114	0.000374	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Prednisone—systemic scleroderma	0.000113	0.000373	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Methotrexate—systemic scleroderma	0.000113	0.000372	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Methotrexate—systemic scleroderma	0.000113	0.000372	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Prednisone—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Gadopentetate dimeglumine—Rash—Prednisone—systemic scleroderma	0.000108	0.000355	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Prednisone—systemic scleroderma	0.000108	0.000355	CcSEcCtD
Gadopentetate dimeglumine—Headache—Prednisone—systemic scleroderma	0.000107	0.000353	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000105	0.000347	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Methotrexate—systemic scleroderma	0.000103	0.000338	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Prednisone—systemic scleroderma	0.000102	0.000335	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Methotrexate—systemic scleroderma	0.000101	0.000333	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Methotrexate—systemic scleroderma	9.79e-05	0.000322	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Methotrexate—systemic scleroderma	9.46e-05	0.000311	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Methotrexate—systemic scleroderma	9.1e-05	0.000299	CcSEcCtD
Gadopentetate dimeglumine—Rash—Methotrexate—systemic scleroderma	9.02e-05	0.000297	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Methotrexate—systemic scleroderma	9.01e-05	0.000297	CcSEcCtD
Gadopentetate dimeglumine—Headache—Methotrexate—systemic scleroderma	8.96e-05	0.000295	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Methotrexate—systemic scleroderma	8.5e-05	0.00028	CcSEcCtD
